Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Yanjun Zhang et al.|Journal of Thoracic Oncology|2021Cited by 311
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY. Wang, Fred R. Hirsch, Tao Jiang et al.|Annals of Oncology|2018Cited by 217
Early detection of lung cancer by using an autoantibody panel in Chinese populationShengxiang Ren, Fred R. Hirsch, Shucai Zhang et al.|OncoImmunology|2017Cited by 203
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinomaTao Jiang, Caicun Zhou|Journal of Hematology & Oncology|2019Cited by 107
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Pingyang Wang et al.|Signal Transduction and Targeted Therapy|2021Cited by 94